ASCO Annual Meeting | Conference

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

June 7th 2024

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

June 6th 2024

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

June 6th 2024

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

June 6th 2024

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

June 5th 2024

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

June 5th 2024

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

June 5th 2024

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

June 5th 2024

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

June 4th 2024

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

June 4th 2024

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

June 4th 2024

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

June 4th 2024

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

June 4th 2024

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma

June 4th 2024

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

June 4th 2024

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC

June 4th 2024

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

June 4th 2024

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

June 3rd 2024

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

June 3rd 2024

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.